1. Home
  2. BBUC vs ADPT Comparison

BBUC vs ADPT Comparison

Compare BBUC & ADPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Brookfield Business Corporation Exchangeable Subordinate Voting Shares

BBUC

Brookfield Business Corporation Exchangeable Subordinate Voting Shares

N/A

Current Price

$28.38

Market Cap

5.5B

Sector

N/A

ML Signal

N/A

Logo Adaptive Biotechnologies Corporation

ADPT

Adaptive Biotechnologies Corporation

N/A

Current Price

$26.67

Market Cap

4.5B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
BBUC
ADPT
Founded
2022
2009
Country
Bermuda
United States
Employees
N/A
N/A
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
5.5B
4.5B
IPO Year
2015
2019

Fundamental Metrics

Financial Performance
Metric
BBUC
ADPT
Price
$28.38
$26.67
Analyst Decision
Buy
Strong Buy
Analyst Count
8
8
Target Price
★ $37.38
$30.21
AVG Volume (30 Days)
272.3K
★ 2.0M
Earning Date
11-05-2026
11-04-2026
Dividend Yield
★ 0.87%
N/A
EPS Growth
N/A
★ 63.89
EPS
★ N/A
N/A
Revenue
N/A
★ $276,976,000.00
Revenue This Year
N/A
$5.03
Revenue Next Year
N/A
$22.97
P/E Ratio
N/A
★ N/A
Revenue Growth
N/A
★ 54.77
52 Week Low
$24.80
$12.00
52 Week High
$38.25
$30.74

Technical Indicators

Market Signals
Indicator
BBUC
ADPT
Relative Strength Index (RSI) 63.51 51.10
Support Level $24.80 $23.76
Resistance Level $32.12 $30.35
Average True Range (ATR) 0.78 1.48
MACD 0.22 0.25
Stochastic Oscillator 79.58 53.35

Price Performance

Historical Comparison
BBUC
ADPT

About BBUC Brookfield Business Corporation Exchangeable Subordinate Voting Shares

Brookfield Business Corp is the operator of vital industrial and business services operations. The company focuses on acquiring market businesses for value, execute its operational improvement plans to increase cash flows and recycle capital to compound long-term growth. Geographically, it derives maximum revenue from the United States, and the rest from Europe, Brazil, Australia, Canada, and others. It operates in four segments within particular sectors namely: business services, infrastructure services, industrials, and corporate. The company derives maximum revenue from Industrials segment engaged in energy storage operations, engineered components manufacturing operations, water and wastewater operations, electric heat tracing systems manufacturer, and other industrials operations.

About ADPT Adaptive Biotechnologies Corporation

Adaptive Biotechnologies Corp is a company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is a test authorized by the FDA for the detection and monitoring of minimal residual disease (MRD) in patients with multiple myeloma (MM), B cell acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia (CLL) and is also available as a CLIA-validated laboratory developed test (LDT) for patients with other lymphoid cancers. The company has two operating segments: Minimal Residual Disease and Immune Medicine. The company generates the majority of its revenue from the Minimal Residual Disease segment.

Share on Social Networks: